Form 4: Tevogen Bio Holdings Officer Sells Shares to Cover Tax Obligations

Neal Flomenberg, Chief Scientific Officer of Tevogen Bio Holdings, sold shares of common stock between March 4th and March 6th, 2025, to cover tax obligations related to the vesting of restricted stock units.

Summary

• Neal Flomenberg, the Chief Scientific Officer of Tevogen Bio Holdings, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the sale of common stock on March 4, 2025, March 5, 2025, and March 6, 2025.
• These sales were made to satisfy tax obligations related to the vesting and subsequent settlement of restricted stock units.
• The sales were not made at the discretion of the reporting person.
• On March 4, 2025, 14,639 shares were sold at an average price of $1.28.
• On March 5, 2025, 110,659 shares were sold at an average price of $1.21.
• On March 6, 2025, 88,519 shares were sold at an average price of $1.10.
• Following these transactions, Flomenberg beneficially owns 4,040,485 shares of Tevogen Bio Holdings Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales for tax purposes. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Key Dates